PeerView Gastroenterology CME/CNE/CPE Video Podcast

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EUX865. CME credit will be available until August 6, 2025.

Prioritising Patient-Centric Care in Biliary Tract Cancer: Leveraging Immunotherapy Platforms to Overcome Challenges in the Advanced Setting

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/VTE865. CME/MOC/NCPD/AAPA credit will be available until July 2, 2025.

Catalysts for Change in Gastric and GEJ Cancer: Digesting New Evidence and Future Directions of Care With Innovative Immunotherapy and Targeted Platforms

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hope For Stomach Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through educational grants from Astellas, BeiGene, and Bristol Myers Squibb.

Disclosure information is available at the beginning of the video presentation.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JPD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.

Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Cholangiocarcinoma Foundation, and the Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Disclosure information is available at the beginning of the video presentation.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RNX865. CME credit will be available until June 19, 2025.

Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure information is available at the beginning of the video presentation.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TCK865. CME/MOC credit will be available until June 14, 2025.

Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Interventional Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VEX865. CME/AAPA credit will be available until April 24, 2025.

Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Diseases: Addressing Shared Pathophysiology With JAK Inhibitors

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Crohn's and Colitis Foundation, National Eczema Association, and Spondylitis Association of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AbbVie.

Disclosure information is available at the beginning of the video presentation.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FYP865. CME credit will be available until April 26, 2025.

The Convergence of Interventional Radiologists and Oncologists in HCC: Shared Decision-Making and Care Coordination at the Center of Personalized Care Across the Disease Continuum

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Eisai Inc.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/DXM865. CME/MOC/AAPA credit will be available until February 12, 2025.

Targeting a Brighter Future for Pediatric Patients With Eosinophilic Esophagitis: Ensuring Prompt Diagnosis and Exploring the Role of Biologic Treatment

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Campaign Urging Research for Eosinophilic Disease. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Joshua B. Wechsler, MD, MSci, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Ellodi Pharmaceuticals; Regeneron Pharmaceuticals, Inc; and Sanofi.
Grant/Research Support from Regeneron Pharmaceuticals, Inc and Sanofi.
Speaker for Regeneron Pharmaceuticals, Inc and Sanofi.

Patient Advocate/Planner
Holly Roland has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/THZ865. CME/MOC/AAPA/IPCE credit will be available until February 26, 2025.

Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Lipika Goyal, MD, MPhil, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alentis Therapeutics AG; Basilea Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.; Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.; QED Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera Biosciences.
Data Safety Monitoring Board for AstraZeneca.

Co-Chair/Planner
Riad Salem, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bard Pharmaceuticals; Boston Scientific Corporation; Cook Medical; Eisai Inc./Merck & Co., Inc.; and Genentech, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.

Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Milind Javle, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.

Faculty/Planner
Tanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.
Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.
Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.
Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.

Faculty/Planner
Rachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.
Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.